ProCE Banner Activity

Overcoming Challenges to CAR T-Cell Therapy During the COVID-19 Pandemic

Clinical Thought
How can we safely administer CAR T-cell therapy to patients during the COVID-19 pandemic? In this commentary, I share strategies from my practice.

Released: March 31, 2021

Expiration: March 30, 2022

Share

Faculty

Caron Jacobson

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Kite Pharma

Faculty Disclosure

Primary Author

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Caron A. Jacobson, MD, has disclosed that she has received consulting fees from AbbVie, Bluebird, Bristol-Myers Squibb/Celgene, Kite, Lonza, Nkarta, Novartis, and Precision Biosciences and funds for research support from Kite.